Climb Bio Inc
NASDAQ:CLYM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lianhe Sowell International Group Ltd
NASDAQ:LHSW
|
CN |
|
KEI Industries Ltd
NSE:KEI
|
IN |
|
E
|
Energy Fuels Inc
AMEX:UUUU
|
US |
|
Sands China Ltd
HKEX:1928
|
MO |
|
Suzano SA
NYSE:SUZ
|
BR |
|
M
|
MariaDB PLC
NYSE:MRDB
|
IE |
|
A
|
Autohellas SA
ATHEX:OTOEL
|
GR |
|
C
|
C banner International Holdings Ltd
HKEX:1028
|
CN |
Climb Bio Inc
Research & Development
Climb Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Climb Bio Inc
NASDAQ:CLYM
|
Research & Development
-$46.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Climb Bio Inc
Glance View
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
See Also
What is Climb Bio Inc's Research & Development?
Research & Development
-46.7m
USD
Based on the financial report for Dec 31, 2025, Climb Bio Inc's Research & Development amounts to -46.7m USD.
What is Climb Bio Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-20%
Over the last year, the Research & Development growth was -302%. The average annual Research & Development growth rates for Climb Bio Inc have been -21% over the past three years , -20% over the past five years .
